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Thesis Abstract
One of the major hallmarks of central nervous system injury is astrocyte 
proliferation. However, not aU astrocytes enter the cell cycle following damage, and the 
mechanism that determines which astrocytes will proliferate and which will remain 
quiescent has not been elucidated. Protein tyrosine phosphorylation has been shown to 
play an important role in the regulation of the cell cycle in a number of different systems, 
and has been implicated in astrocyte proliferation and differentiation. The protein tyrosine 
phosphatase SHP-1 modulates cellular proliferation in the hematopoietic system and is 
involved in various growth factor signal transduction cascades. Our laboratory has 
previously shown an increase in SHP-1 immunoreactivity in a subpopulation of astrocytes 
following deafferentation of the chick auditory brainstem. These SHP-1-positive cells 
appear to be those that do not enter the cell cycle following deafferentation. The present 
study examined whether manipulation of cellular proliferation in vitro modifies the 
expression of SHP-1 immunoreactivity and attempted to identify factors that may contribute 
to the increase in SHP-1 expression following CNS injury.
Mixed neural/glial cultures were prepared from E14 chick brainstems (8-30 
animals/run). SHP-1 immunoreactivity was examined when the cultures were growing, 
growth arrested, and growing again after the réintroduction of serum into the cultures. In 
actively proliferating cultures, SHP-1 immunoreactivity is localized to the cytoplasm of a 
subset of cells, while in growth arrested cultures, SHP-1 immunoreactivity appears to be 
localized to the nucleus of some cells. Cultures which have been induced to divide again 
following growth arrest contain numerous that once again exhibit a cytoplasmic distribution 
of SHP-1.
The protein tyrosine phosphatase (FTPase) inhibitor sodium orthovanadate was 
then introduced into growing cultures and the rate of proliferation was examined after 
PTPase activity was inhibited. Sodium orthovanadate was found to cause an increase in 
proliferation but does not appear to dramatically alter either SHP-1 intensity or distribution 
in these cultures.
Neuronal debris as well as various growth factors have been shown to be mitogenic 
for glial cells and are thought to play a role in the glial response to injury. SHP-1 has been 
shown to interact with several growth factors, including epidermal growth factor (EGF), 
interleukin-3 (IL-3) and granulocyte macrophage-colony stimulating factor (GM-CSF). All 
three growth factors are mitogenic in our culture system and also resulted in slightly 
differing patterns of SHP-1 expression. Addition of EGF to growth arrested cultures 
results in a nuclear distribution of SHP-1, while addition of GM-CSF or IL-3 produces 
both a cytoplasmic and nuclear distribution of SHP-1 immunoreactivity.
Finally, the role of neuronal debris on SHP-1 expression was examined by 
selectively killing neurons by excitotoxicity in confluent cultures. While SHP-1 positive 
ceUs can be found next to healthy neurons, dead or dying neurons are found in areas 
devoid of SHP-1 positive cells. This is in contrast to the pattern observed for glial 
fibrillary acidic protein (GFAP) positive astrocytes, which are often located directly under, 
or adjacent to, dying neurons.
These results demonstrate that SHP-1 expression can be altered by modulating both 
cellular proliferation and by manipulating the extracellular environment. Significantly, 
inhibition of tyrosine phosphatase activity results in increased proliferation, indicating that 
tyrosine phosphatases such as SHP-1 may play a key role in regulating the glial response to 
injury.
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INTRO DUCTIO N
The astrocyte response to central nervous (CNS) injury has been 
traditionally characterized in terms of morphological changes, including 
proliferation, process extension, and increased levels of the glial 
intermediate fibrillary acidic protein (GFAP; Reier and Houle 1988; Reier et 
al. 1983; Graeber and Kreutzberg 1986; Graeber and Kreutzberg 1988; 
Tetzlaff et al. 1988; Condorelli et al. 1990; Steward et al. 1990). Astrocytic 
proliferation following injury results in an astroglial scar and these events 
are referred to as “reactive gliosis” (Reier and Houle 1988). While it is 
generally believed that the formation of the neuro/glial scar is an 
impediment to axonal regeneration (Reier and Houle 1988), many reactive 
astrocytes appear to engage in activities that appear to promote rather 
than inhibit neuronal regeneration. Such activities include the 
phagocytosis of neuronal debris, reconstruction of a functional neural 
tissue, reconstitution of glial limitans, synthesis of extracellular matrix 
proteins, and the synthesis of numerous neurotrophic factors (which are 
thought to enhance neuronal survival and induce neuronal growth and 
differentiation; Reier and Houle 1988; Vaca and Wendt 1992; Carmen- 
Krzan et al. 1991; Banker 1980; McCafferty 1984). While the end result is 
well characterized, neither the signals that regulate astrocyte proliferation 
following injury, nor the basis on which certain subsets of astrocytes enter 
the cell cycle are well understood. The process, however, must be well 
controlled to allow for the formation of a limited glial scar, as massive 
astrocyte proliferation leading to large glial masses (i.e. tumors) at the site 
of injury does not occur. It is clear that reactive astrocytes have
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developed control mechanisms that limit both the window of time in which 
astrocytes proliferate following CNS damage, as well as the number of cells 
that actually progress through the cell cycle. The role that proliferating vs. 
non-proliferating astrocytes play following CNS damage remains to be 
elucidated and it may be that those signals that send certain populations of 
astrocytes into the cell cycle also influence the degree of functional 
recovery that can occur after damage.
Previous studies in our laboratory have found a subset of astrocytes 
in the chick auditory brainstem that upregulate the expression of the 
protein tyrosine phosphatase SHP-1 following CNS injury. It may be that 
this enzyme plays a role in regulating which astrocytes enter the cell cycle 
following damage.
Cell Cycle Regulation
The phases of the cell cycle are classified as follows: mitosis (M), 
first gap (Gl), DNA synthesis (S) and second gap (02). There is also a 
resting stage (Go) of variable duration from early Gl. The phases are 
defined by cytologic criteria and different protein complexes are activated 
in order to trigger progression through the cell cycle (Grana and Reddy 
1995). The advance through checkpoints (in particular Gl-S and G2-M) is 
regulated by protein complexes composed of a regulatory protein (cyclin) 
and a catalytic protein (cyclin-dependent kinase; CDK) (Cavalla and 
Schiffer 1997; Schiffer et al. 1997). These protein complexes form the core
regulatory machinery for the cell cycle and loss of these regulatory 
mechanisms will result in uncontrolled proliferation.
Protein Tyrosine Phosphorylation
The phosphorylation state of proteins and enzymes is critical for 
many cellular functions including cell division. The phosphorylation of 
tyrosine residues has been shown to regulate both cellular proliferation as 
well as differentiation (Bishop 1991: Cantley et al. 1991; Hunter 1991). 
This phosphorylation is regulated by both protein tyrosine kinases (PTKs), 
which phosphorylate tyrosine residues, and protein tyrosine phosphatases 
(PTPs), which dephosphorylate tyrosine residues. However, it is clear that 
the balance between the activities of PTKs and PTPs is critical for both 
cellular proliferation and differentiation.
Protein tyrosine phosphatases (PTPs) have been shown to both 
decrease as well as indirectly increase tyrosine phosphorylation. The PTPs 
are obviously able to dephosphorylate proteins, including kinases, which 
in some circumstances leads to an increase in kinase activity with a 
resulting increase in phosphorylation. While there is evidence that PTPs 
can reverse the effect of PTKs, there is also increasing evidence that PTPs 
are involved in a synergistic effect with PTKs (Walton and Dixon 1993; 
Saito and Streuli, 1991; Fischer et al. 1991; Brautigan 1992).
Of particular interest is the fact that protein tyrosine 
phosphorylation has also been implicated in both astrocyte proliferation 
and differentiation. The differentiation of 02A progenitor cells into type 2
astrocytes results in a decrease in several tyrosine phosphorylated proteins 
(Ingraham and Maness 1990). In addition, the phorbol ester phorbol 12- 
myristate-13-acetate (PMA), which has been shown to induce synthesis of 
the protein tyrosine phosphatase SHP-1 (Zhao et al. 1994), also induces 
changes in astrocyte morphology (Harrison and Mobley 1991). Growth 
factors that activate protein tyrosine kinase receptors, including epidermal 
growth factor, fibroblast growth factor, platelet-derived growth factor, 
interleukin-1, and insulin-like growth factor, are mitogenic for astrocytes in 
vitro (Huff and Schrier 1990; Malhotra et al. 1990; Langan et al. 1994).
Finally, modulation of tyrosine phosphorylation mediated by PTPs, 
participates in both cell cycle regulation and differentiation. Whether 
these enzymes activate or inhibit cell division appears to be dependent 
upon the individual phosphatase and the cellular environment in which it 
is expressed (Lau and Bay link 1993; Neel 1993).
Protein Tyrosine Phosphatase SHP-1
SHP-1 (also known as PTPIC, SHPTP-1, SHP, and HCP) is a 
cytoplasmic tyrosine phosphatase. It contains 2 5rc-homolgy 2 (SH2) 
domains, an uninterrupted PTP region, and a C-terminal extension that has 
several potential phosphorylation sites. The SH2 domain is a conserved 
region of about 100 amino acids and was originally identified in multiple 
members of the src subfamily of non-transmembrane PTKs. The SH2 
domains fall within a non-catalytic region of the cytoplasmic protein 
tyrosine kinases and are thought to be involved the regulation of the
kinase’s activity (Sadowski et al. 1986). The structure of the SH2 domain 
has been identified in other cytoplasmic signaling proteins (Feng and 
Pawson 1994) and it is this structure that promotes protein-protein 
interaction by binding to specific phosphorylated tyrosine residues (Koch 
et al. 1991; for review see Schlessinger and Ullrich 1992). The SH2 
domains of PTPs exert an inhibitory influence on the activity of these 
enzymes when not engaged. When the SH2 domains are engaged by 
protein substrates, the enzyme becomes activated (Neel 1993). Recent 
studies have also shown that recombinant SHP-1 lacking its SH2 domains 
is enzymatically activated against phosphotyrosyl peptides (Pei et al. 1993; 
Townley et al. 1993).
The C-terminal has also been shown to be important in the 
activation of the phosphatase. The C-terminus of the phosphatase serves 
as an auto-inhibitor of this enzyme. Limited trypsinolysis of SHP-1, which 
results in the removal of the C-terminal 41 amino acids, leads to substantial 
activation (Zhao et al. 1993a; 1993b). The C-terminal domain of SHP-1 
may serve both to fold the enzyme into proper conformation to bind 
protein substrates and also inhibit catalysis. Finally, it has been shown that 
when SHP-1 is activated, it translocates to a hpid membrane (Zhao et al.
1994). The specific cellular membrane has yet to be identified.
SHP-1 has been most thoroughly characterized in hematopoietic 
cells, where it is expressed strongly (Plutzky et al. 1992; Yi et al. 1993; 
David et al. 1995; Krautwald et al. 1996). However, SHP-1 has also been 
found in a variety of cells including: human epithelial carcinoma cells 
(Tomic et al. 1995), human cervical carcinoma cells (You and Zhao 1997),
human embryonic kidney cells (Bouchard et al. 1994), rat liver cells (Ram 
and Waxman 1997), rat pancreatic tumor cells (Cambillau et al. 1995) and 
mouse astrocytes (Massa and Wu 1996).
In general, SHP-1 phosphatase activity is inversely related to 
growth and proliferation of cells. Recently, several groups have studied 
SHP-1 expression in different systems. The consensus has been that SHP-1 
is playing a negative role in cellular growth and proliferation. For example 
somatostatin inhibits cellular proliferation and stimulates SHP-1 activity in 
Chinese hamster ovary cells (Lopez et al. 1996; 1997). The glucocorticoid 
dexamethasone inhibits proliferation of rat pancreatic tumor acinar cells 
and selectively increases SHP-1 expression and activation several-fold 
(Cambillau et al. 1995). Phorbol esters inhibit proliferative activity in 
human leukemia cells and stimulate expression and activity of SHP-1 
(Uchida et al. 1993: Zhao et al. 1994). In a related observation, the 
interleukin-3-induced growth stimulation of hematopoietic cells is 
suppressed by the induction of SHP-1 expression (Yi et al. 1993). 
However, a negative role for SHP-1 in cellular proliferation is not universal. 
Overexpression of SHP-1 in epidermal growth-factor-activated human 
embryonic kidney cells suggests a positive role for the phosphatase in 
proliferative activity (Su et al. 1996). It has become clear that the role of 
SHP-1 in growth, proliferation, and differentiation of cells is apparently 
dependent on context: including cell type, signaling molecules, and 
perhaps other factors.
The signal transduction pathway of SHP-1 has yet to be fully 
elucidated. However, SHP-1 has been shown to play a role in growth
factor mediated signal transduction in a variety of different cells. For 
example, SHP-1 binds to the interleukin 3 (IL-3) receptor following ligand 
binding and can dephosphorylate the B chain of the receptor in vitro (Yi 
and Ihle 1993). SHP-1 also associates with activated EGF receptors (You 
and Zhao 1997; Tenev et al. 1997) and may also dephosphorylate novel 
substrates critical for GM-CSF signaling in mouse macrophages (Yang et 
al. 1998). However, the in vivo target substrates and resulting signal 
transduction cascades activated by SHP-1 have not been determined for 
most cells, and probably differ among various cell types.
As mentioned above, the role of SHP-1 in vivo remains to be 
elucidated. The best characterized in vivo model is a mouse knockout for 
SHP-1; ihQ Motheaten (me) mouse, named after the motheaten appearance 
of their coats. Classically viewed as a severe combined immunodeficency 
disease. Motheaten mice do have profound abnormalities in immune 
function and survive only a few weeks to a few months (Bignon and 
Siminovitch 1994; Shultz and Sidman 1987). There is also a profound 
auto-immunity, marked by dramatic macrophage hyperproliferation.
SHP-1 Expression in Astrocytes of the Deafferented Auditory 
Brainstem
Our laboratory has previously described a subset of astrocytes in 
the chick auditory brainstem that express SHP-1 (Lurie et al. 1993). SHP-1 
immunoreactivity increases strongly in response to deafferentation, and 
this is correlated with increased astrocyte proliferation. However, SHP-1
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immunoreactivity appears to be upregulated in astrocytes that fail to enter 
the cell cycle following injury (Lurie et al. 1997; Lurie et al. 1998). Thus, 
SHP-1 may play a role in regulating the number of astrocytes that 
proliferate in response to deafferentation, thereby limiting the size of the 
glial scar. A related observation has been in the rat hippocampus, where 
SHP-1 inununoreactivity in glial cells increases following either excitotoxic 
or metabolic-induced injury (Willis et al. 1997). Taken together, these 
results clearly indicate that SHP-1 is an important component of the CNS 
response to injury.
We hypothesize that once a signal for proliferation has been 
initiated (such as deafferentation or other CNS injury) the affected glial 
cells can take one of two different pathways. One pathway is to divide in 
response to the signal, the other pathway is to actively prevent cell 
division in the presence of a signal to divide. SHP-1 may be part of the 
intracellular cascade that is turned on to prevent some glial cells from 
proliferating in the presence of an extrinsic signal to divide. When there is 
no such signal to divide, i.e. in the uninjured brain, there is no need to 
upregulate SHP-1, and it is expression remains low. Only when there is an 
extrinsic signal to divide does a regulatory mechanism become important, 
and SHP-1 is upregulated. Obviously, some sort of regulatory mechanism 
must be activated in order to modulate the glial response to injury. If every 
astrocyte or microglia entered the cell cycle following damage, they would 
overrun each other with potentially negative consequences.
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Specific Objectives of the Current Project
The overall goal of this project was to determine whether SHP-1 
played a role in regulating glial proliferation in vitro. Specifically, we 
asked three questions: 1) Does manipulation of the cell cycle change
either the amount and/or distribution of SHP-1?, and 2) Does inhibition of 
protein tyrosine phosphatase activity alter glial proliferation?, and 3) What 
extracellular signals lead to changes in both SHP-1 expression and glial 
proliferation? In order to address these questions, the following series of 
experiments were performed using mixed neural/glial cultures from the 
chick brainstem.
1. The cell cycle was manipulated in vitro in order to observe changes in 
SHP-1 expression.
2. The tyrosine phosphatase inhibitor sodium orthovanadate was added to 
cultures and changes in both SHP-1 expression and proliferation were 
monitored.
3. The growth factors EGF, IL-3 and GM-CSF were added to cultures in 
order to determine whether these factors played a role in upregulating 
SHP-1 expression following injury in vivo.
4. Neurons in mixed cultures were killed using the excitotoxin NMDA in 
order to determine whether neuronal death plays a role in upregulating 
SHP-1 expression following injury in vivo.
MATERIALS AND METHODS 
Subjects
Embryonic chicks (white leghorn; Truslow Farms Chestertown, 
MD) were used for this investigation. Fertilized eggs were incubated at 
37-38% in a humidified environment in the University of Montana 
AAALAC-approved animal care facilities. Brainstems were removed from 
stage 41 (embryonic day E-14) animals using the Hamburger and 
Hamilton’s (1951) staging scheme. Eight to thirty embryos were used for 
each experiment. All procedures were approved by the University of 
Montana Institutional Animal Care and Use Committee.
In vitro preparation
Embryonic day-14 chicks were sacrificed by decapitation. The 
brainstems were dissected from the embryos and freed of the meninges 
(performed in calcium/magnesium free buffer: CMF). The tissue was then 
transferred to a 35 ml petri dish, minced with a sterile razor blade in Earle’s 
Balanced Salt Solution (EBSS), and then placed in a vial containing 20 
units papain/500 units DNase in 0.5 mM EDTA (Worthington Biochemical 
Corp.) The vial containing the cells was placed in a 37% water bath for 
20 minutes with sterile 95% COj bubbled through the solution.
Cells were then gently triturated with a flame constricted glass pipette for 
5 minutes. The suspension was next placed in a 15 ml centrifuge tube and 
centrifuged at 300 x g for five minutes at room temperature. The
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supernatant was then discarded and 2.7 mis EBSS/333 units DNase and 
1.665 units ovomucoid protease inhibitor was added to the cells. The 
solution was next centrifuged at 70 x g for six minutes (Worthington 
Biochemical Corp.; Papain Dissociation System). The pellet was 
resuspended in 4 mis of EMEM (minimum essential medium with EBSS; 
GibcoBRL) containing 10% horse serum (HS; GibcoBRL), 10% fetal 
bovine serum (PBS) (Hyclone), 1% penicillin-streptomycin (GibcoBRL), 2 
mM L-glutamine and 1% Fungizone (GibcoBRL). Cells were counted 
using a hemacytometer (Fisher Scientific), and then plated in 12 well plates 
with poly-L-lysine coated coverslips at a seeding density of 5 X 10̂  
cells/well. After plating, the cells were placed in an incubator at 37®C 
under an atmosphere of 5% CO  ̂in air.
Culture Experiments
Manipulation o f the cell cycle
Once the cultures were placed in the incubators they were allowed 
to grow for 6 days. At day 6, one third of the plates were pulsed for 6 
hours with the thymidine analog, BrdU (Ipg/ml; Sigma), to label dividing 
cells. After 6 hours, the cultures were fixed in ice-cold methanol for 2 
minutes or 4% paraformaldehyde for 15 minutes, rinsed in 0.1 M Tris buffer, 
pH 7.4 and then processed for BrdU, SHP-1, GFAP, 0X42, CNP and 
Neurofilament immunohistochemistry. The remaining plates were then 
gradually serum depleted over the next 3 days in order to growth arrest 
the cultures. This was accomplished by gradually reducing the 
concentrations of fetal bovine serum and horse serum from 10% (days 1-6)
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to 5% (day 6) to 3% (day 1 \ and finally 1% (day 8). On the 9th day the 
medium was changed to a Neuralbasal medium with B-27 supplement 
(GibcoBRL). This medium contains no serum or proliferative growth 
factors but has been shown to sustain cells in vitro (Brewer et al., 1993;
1995) The cultures were then left in the Neuralbasal medium for 6 days 
(with a media change at day 3). At day 15, half of the cultures were pulsed 
with BrdU for 6 hours, fixed in ice-cold methanol and processed for the 
antibodies stated above. Serum was added to the remaining cultures at 
day 15 (EMEM 10% FBS/10% HS) and the cells were allowed to grow for 
an additional 3 days. At day 18 the remaining plates were pulsed with 
BrdU for 6 hours, fixed, and processed for immunocytochemistry.
Addition o f the phosphatase inhibitor Sodium Orthovanadate
Cultures were allowed to grow for 7 days in EMEM 10% FBS/10% 
HS (at day 6 the media was changed). On day 7, sodium orthovanadate 
was added to the cultures at concentrations of 10, 20, 30, 40 and 50 p,M. 
Twenty-four hours after the addition of sodium orthovanadate, the 
cultures were pulsed with BrdU for 6 hours. The cells were then fixed and 
processed for BrdU and SHP-1 immunohistochemistry.
Addition o f growth factors
For some experiments, growth factors instead of serum were added 
back to the cultures at day 15. These growth factors included EGF, IL-3 
and GM-CSF (Becton Dickinson; see results for specific concentrations). 
The cultures were then pulsed with BrdU at day 16 (24 hours after
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addition of growth factors or serum) and day 18 (72 hours after addition of 
growth factors or serum). After each pulse the cells were fixed with either 
ice-cold methanol or 4% paraformaldehyde for 15 minutes and then 
processed for BrdU and SHP-1 immunohistochemistry.
Addition o f NMDA
Cultures were allowed to grow in EMEM 10% FBS/10% HS for 11 
days. The media was changed on days 6, 9 and 11. N-methyl-D-aspartate 
(NMDA; Tocris) was introduced on day 11 at concentrations of 25, 50, 75 
and lOOjiM. Twenty-four and 48 hours after the addition of NMDA, the 
cultures were pulsed for 6 hours with BrdU. The cells were then fixed and 
processed for BrdU, SHP-1, GFAP, and Neurofilament 
immunohistochemistry.
Immunohistochemical procedures
Cultures were first rinsed twice for 5 minutes with 0.1 M Tris-HCl 
buffer, pH 7.4. Cells which were labeled for CNP and 0X42 were fixed in 
4% paraformaldehyde for 15 minutes, all others were fixed in ice-cold 
methanol for 2 minutes. Cells were next rinsed in 0.1 M Tris-HCl buffer, 
pH 7.4 and Tris-HCl buffer, pH 7.4 with 1% bovine serum albumin (BSA; 
Sigma). Two additional steps were performed when labeling for BrdU; a 5 
minute rinse in 0.0IM HCl followed by an additional Tris-HCl, pH 7.4 
rinse. The cells were then incubated for 20 minutes in 4% normal horse 
serum for monoclonal antibodies and 4% normal goat serum for polyclonal 
antibodies. All immunohistochemical reagents were prepared in 1%
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BSA/1 % sodium azide in Tris-HCl buffer, pH 7.4 [except for the avidin 
biotin complex (ABC) reagent]. The cultures were incubated in the 
primary antibody overnight; anti-BrdU (1:2000; Becton Dickinson); 205 
(1:2000; a generous gift from Dr. Shen, Montreal Canada); anti-GFAP 
(1:1500; DAKO); anti-Neurofilament (1:800; courtesy of Dr. Virginia Lee, 
Philadelphia, PA.); anti-CNP (1:100; Promega); anti-OX42 (1:500; Serotec). 
The next day, the cells were washed in Tris-HCl buffers, pH 7.4, incubated 
in either biotinylated horse anti-mouse or biotinylated goat anti-rabbit 
(monoclonal and polyclonal, respectively) at a concentration of 1:400. The 
cells were then washed in Tris buffers, incubated in ABC (1:6 dilution; 
Vectastain Elite ABC kit; Vector Labs) for 1 hour. The cells were rinsed for 
10 minutes in Tris and developed with diaminobenzidine as the chromagen 
(0.5 mg/ml; Sigma) with 0.1% H2 O2  and 1 mM imidazole in Tris-HCl buffer, 
pH 7.4. For BrdU the diaminobenzidine was intensified with 0.08% nickel 
chloride to create a black rather than a brown reaction product. The 
coverslips were then dehydrated and covers lipped using DPX (BDH 
Laboratories).
Double-label immunohistochemistry
Cultures were rinsed twice for 5 minutes with O.IM Tris-HCl, pH 7.4 
and then fixed. Cells were then rinsed three times for 5 minutes with 
phosphate buffer saline (PBS), pH 7.4. Cells were blocked with either 4% 
normal horse serum (NHS) or 4% normal goat serum for 20 minutes. This 
and all other immunocytochemical reagents were prepared in 1% BSA in 
PBS. The cells were next incubated in monoclonal antibodies (CNP-1:5
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0X42-1:10 and Neurofilament-1:10) or polyclonal antibodies (SHP-1-1:400, 
GFAP-1:10) overnight at room temperature. The next day the cells were 
rinsed three times for 5 minutes each with PBS, then incubated for 1 hour 
in 1:200 biotinylated goat anti-rabbit linked to FTTC or Cy3 or 1:200 
biotinylated horse anti-mouse linked to FTTC or Cy3 (Vector Labs). Cells 
were then rinsed three times for 15 minutes in PBS, rinsed in ddH^O and 
coverslipped with vectashield mounting media (Vector Labs).
Covalent Coupling of Fluorescein to Antibody
The polyclonal antibody ghal fibrillary acidic protein (GFAP) was 
directly linked to fluorescein to allow for double labeling with two 
polyclonal antibodies. This protocol is modified from Schreiber and 
Haimovich (1983). Briefly, in the absence of light fluorescein 
isothiocyanate (FTTC) was dissolved in absolute ethanol, at a 
concentration of 5 mg/ml. 250 |il IM sodium carbonate buffer (pH 9.0) 
and the appropriate amount of FTTC (25 jig FITC/mg IgG) was added to 
the GFAP antibody solution (Dako), vortexed and allowed to come to 
ambient temperature. The FITC/antibody solution was passed over a G-50 
Sephadex column. The FITC/antibody solution which passed through the 
column was collected and the concentration of fluorescein-conjugated IgG 
(mg/ml) and molar ratio of dye/protein was determined by absorbance at 
280 nm and 493 nm.
16
Immunohistochemical analysis
Quantification o f BrdU labeled cells
Cultures were viewed with a Nikon Eclipse E800 microscope at 
magnifications ranging from 4-60X. BrdU positive cells within the cultures 
were counted using NIH Image Analysis Program 1.61.
With a random start, nine random fields of 1.78 mm  ̂were analyzed 
for each well. Slides were viewed with a microscope that was attached to 
a COHU high performance CCD video camera connected to a Power 
Macintosh 8600/200 computer. NIH Image 1.61 (image analysis software) 
allowed the analysis of the digitized images. Once the image was digitally 
captured the NIH Image 1.61 program macros were used to count the 
number of BrdU positive cells. The total number of labeled cells were 
calculated and averaged over the controls. Significant differences were 
determined by a one-way ANOVA.
Quantification o f phosphatase immunoreactivity
The density of the phosphatase immunoreactivity within the 
cultures was determined by using NIH Image Analysis Program 1.61. As 
stated above, nine random fields were selected and the image captured on 
the viewing screen. Once captured a density threshold was set for each 
culture. The mean density was measured and averaged over control 
density. Significant differences were determined by a one-way ANOVA.
RESULTS 
Neural/Glial Culture
Mixed neural/glial cultures were prepared from E14 chick 
brainstems. Cultures contained both neural and glial cells as demonstrated 
by immunocytochemical labeling for various cell types. All cultures 
contained a small number of neurons that were immunopositive for 
neurofilament (Fig. 1 A). Neurons were observed to be present at all times, 
even through day 18 in culture. The neurons appeared to be viable and 
healthy with intact cell bodies and many long processes. In some cases, 
neurons appeared to be contacting each other (Fig. lA). In addition, the 
cultures contained astrocytes, oligodendrocytes, and microgha as 
demonstrated by immunostaining for GFAP, CNP, and 0X42 respectively 
(Fig. IB, C, D). Finally, a subset of cells were inununopositive for SHP-1 in 
vitro (Fig. IE). Staining was largely confined to the cytoplasm and the 
initial segment of some glial processes. Thus, the in vitro system contains 
neurons, all glial sub-types, and SHP-14- cells.
Identification of SHP-1 positive cells
A subset of all three glial cell types appear to express SHP-1 in 
vitro. Control cultures (day 12) were double-labeled for SHP-1 and either 
Neurofilament, GFAP, 0X42, and CNP. A few astrocytes, microglia, and 
oligodendrocytes were found to be SHP-1+ (Fig. 2A, B, C). Neurons did 
not appear to express SHP-1 (Fig. 2D). The presence of SHP-1 in aU three
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Fig. 1. Mixed neural glial cultures contain neurons, astrocytes, 
oligodenrocytes, microglia, and SHP-1+ cells (Day-18 in culture). A) 
Neurons immunostained for neurofilament (RMO 270). Two large healthy 
neurons (large arrows) with intertwined processes (small arrow). B) The 
cultures contain many GFAP+ astrocytes (arrows). Bar=50)im (A and B). 
C) CNP+ oligodendrocytes are found throughout the culture (arrows). D) 
0X424- microglia are present in the culture (arrows). E) Many SHP-14- 
cells are found in day 6 growing cultures. Note the cytoplasmic 
localization of the immunoreactivity (arrows). Bar=30|im (C, D, and E)
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Fig. 2. SHP-1 positive cells (red) at day 13 in culture. A) Few 
differentiated GFAP+ astrocytes (green) are also SHP-1+ (arrows). B) 
Many less differentiated GFAP+ (green) cells are SHP-1+ (arrows). C) 
Several CNP+ oligodenrocytes (green) are SHP-1+ (arrow). D) Several 
0X42+ microglia (green) are SHP-1+ (arrows). Bar=20)im E) No neurons 
(green; arrow) appear to express SHP-1. Bar=80|iim
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glial cell types differs from previous findings in vivo, where only astrocytes 
appear to become immunopositive for SHP-1 following deafferentation. In 
the avian brainstem, astrocytes appear to be the only type of glial cell that 
proliferates following deafferentation (Lurie and Rubel 1996; Lurie et al. 
1998). In this system, the onset of astrocyte proliferation is correlated with 
significant increases in SHP-1 immunoreactivity. However SHP-1+ cells do 
not appear to enter the cell cycle. Therefore, it has been hypothesized that 
the expression of SHP-1 plays a role in regulating the mitotic behavior of 
these astrocytes (Lurie et al. 1998). Presumably all types of glial cells 
proliferate in culture, and thus it is not unexpected that SHP-1 is expressed 
by a sub-population of all three glial types.
Cellular proliferation.
In order to determine whether SHP-1 is playing a role in glial 
proliferation, the expression of SHP-1 was examined when cultures were 
either growing or growth arrested. To establish the amount of glial 
proliferation during the various growth conditions, 6 hour pulses of the 
thymidine analogue 5’-Bromodeoxyuridine (BrdU) was introduced into 
the cultures in order to label dividing cells. Visual inspection of BrdU- 
labeled cells at three times points, growing (Day-6), growth arrested (Day- 
15) and serum addition/growing (Day-18), revealed that manipulation of 
glial proliferation could be accomplished by serum deprivation (Fig. 3). 
When cultures were growing towards confluence, there were many BrdU 
positive cells (Day-6,growing; Fig. 3A). The number of proliferating cells 
decreased after serum deprivation (Day-15, growth arrested; Fig. 3B) and
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Fig. 3. Brdu-positive cells during manipulation of the cell cycle. A) Note 
the many BrdU+ cells at day 6 in culture (growing) (arrows). B) The 
number of BrdU+ cells dramatically decreases after 6 days of serum 
deprivation (Day-15 in culture; growth arrested) (arrows). C) 
Réintroduction of serum for 3 days (Day-18 in culture) results in increased 
numbers of BrdU+ cells (arrows). Bar=50 pm
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Figure 4: Quantification o f proliferation o f cultures during different 
growing conditions as described in methods. The Y-axis represents the 
average number o f BrdU-labeled cells in nine random fields with each 
culture. Serum depletion results in a significant decrease in proliferation. 
Re-introduction o f serum results in a significant increase in proliferation 
when compared to growth arrested cultures. Significant differences among 
growing, growth arrested and serum addition cultures were determined 
using a one-way ANO VA, * p < 0.0001.
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Fig. 5 SHP-1 immunoreactivity of cultures during manipulation of the cell 
cycle. A) Growing cultures (Day-6) contain numerous SHP-1+ cells. Note 
the cytoplasmic staining (arrows). B) Growth arrested cultures (Day-15) 
contain areas devoid of any immunoreactivity. C) Some areas of the 
growth arrested cultures contain clusters (approximately 30%) of SHP-14- 
cells with a nuclear distribution of immunoreactivity (arrows). D) Re- 
introduction of serum results in growing cultures (Day-18) with scattered 
SHP-14- cells. The immunoreactivity is once again localized to the 
cytoplasm (arrows). Bar=30|im
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then increased again after serum was re-introduced into the cultures for 
three days (Day-18, serum addition; Fig. 3C). The number of BrdU-labeled 
cells was then quantified using image analysis techniques. Serum 
deprivation reduced the number of proliferating cells by 2.5 fold (Fig. 4); 
however, we were unable to completely eliminate all cellular division by 
serum depletion. The addition of serum back into the cultures increased 
proliferation to within 73% of the original growing cultures (Fig. 4).
SHP-1 expression was then correlated to the different growth 
conditions. At the earliest time point (Day-6), SHP-1 immunoreactivity was 
distributed within the cytoplasm and initial segments of the processes in 
some glial cells (Fig. 5A). However, when the cultures were growth 
arrested (Day-15), there was a distinct change in the pattern of SHP-1 
immunoreactivity which fell into one of two distributions. Some areas of 
the culture contained very little immunostaining for SHP-1 (Fig. 5B) while 
in other areas the immunoreactivity for SHP-1 was localized to the nucleus 
of clusters of cells (Fig. 5C). When cultures were induced to divide again 
by re-introduction of serum, SHP-1 immunoreactivity once again appeared 
to have a cytoplasmic distribution (Fig. 5D).
Addition of Sodium Orthovanadate
If SHP-1 plays a role in negatively regulating the glial cell cycle in 
vitro, then inhibiting this phosphatase should result in increased glial 
proliferation. In order to test this hypothesis, the nonselective tyrosine 
phosphatase inhibitor sodium orthovanadate was added to growing 
cultures at day 7 for 24 hr. Some cultures were then pulsed with BrdU for
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the last 6 hours of the 24 hr vanadate treatment and other cultures were 
immunostained for SHP-1. Vanadate was found to be toxic to the cultures 
at concentrations higher than 100 |iM, and caused the cells to lift off of the 
coverslips and the cultures to become patchy (data not shown). However, 
at concentrations below 100 |iM the cells appeared healthy. Adding 
vanadate to growing mixed neural/glial cultures resulted in a dose 
dependent increase in cellular proliferation. Increases in cell division were 
observed with the addition of as little as 10 |iM of vanadate to the cultures 
and significant increases were observed with 20 |iM of vanadate (Fig. 6A, 
C, E and Fig. 7). The highest dose of vanadate which did not produce cell 
toxicity (50 jiM) resulted in an almost 3-fold increase in cellular 
proliferation over controls (Fig. 7).
Interestingly, the expression of SHP-1 did not change significantly 
with the addition of vanadate. While concentrations of 30 and 50 pM of 
sodium orthovanadate appeared upon visual inspection to result in slightly 
darker SHP-1 immunolabeling, quantification of the density of staining 
throughout the cultures did not reveal significant increases over control 
(Fig. 6B, D, F and Fig. 8).
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Fig. 6 Effects of sodium orthovanadate on proliferation and SHP-1 
immunoreactivity. A and B- control cultures. C and D- 24 hr. of 30 jiM 
vanadate. E and F- 24 hr. of 50 |LiM vanadate. (A, C, and E) Cultures are 
labeled for BrdU-immunohistochemstry. Note the increase in the number 
of BrduU-i- cells with increasing concentrations of vanadate. Bar=50 pm. 
(B, D, and F) Immunostaining for SHP-1 does not appear to change 
following the addition of vanadate. A similar number of cells continue to 
display a cytoplasmic distribution of SHP-1 (arrows). Bar=30 pm
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24 hours after addition of sodium orthovanadate
2.5 H
CD
o
"D
(D
CD
-Q
_Ç5
I
3
P
CÛ
o
g
CO
CL
1 .5 ”
T
0 .5 -
Control
All concentrations are |iM.
Figure 7: The ratio o f the number of BrdU+ cells after treatment of sodium 
orthovanadate over control. The Y-axis represents the ratio of BrdU-labeled cells over 
the control in nine random fields within each culture. There is a significant increase in
proliferation at concentrations of vanadate > 20 fiM. Significant differences between 
control and vanadate concentrations were determined using a one-way ANOVA, * p <  
0 .01 .
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SHP-1 Density Quantification
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Figure 8: Quantification o f density o f immunoreactivity o f SHP-1 after the 
addition o f vanadate to the cultures. The Y-axis represents the ratio o f  
density o f SHP-1 immunoreactivity over the control cultures. There was no
significance difference among the control, 30 |iM , and 50 p.M vanadate 
groups, determined using a one-way ANOVA.
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Addition of Growth Factors
Growth factors are thought to play a key role in regulating the glial 
response to injury. We therefore investigated whether a variety of growth 
factors influenced SHP-1 expression in vitro. We chose to examine three 
growth factors that have been shown to interact with either the SHP-1 
protein itself and/or lead to increased glial proliferation in other CNS 
culture systems.
EOF addition
Epidermal growth factor (EOF) has been demonstrated to be 
mitogenic for a variety of astrocytes in vitro (Langan et al. 1994; Huff and 
Scheier 1990). Our cultures also responded to EOF with an increase in 
cellular proliferation. To establish the amount of glial proliferation induced 
by the addition of EOF, BrdU was introduced into the cultures during the 
last 6 hours of either 24 or 72 hr. of EOF treatment in order to label 
dividing cells. Parallel control cultures received serum rather than EOF and 
were also pulsed with BrdU. The number of BrdU-labeled cells within nine 
random fields per culture were then counted.
EOF significantly increased proliferation at all concentrations (20- 
320 ng/ml) when compared to growth arrested cultures at 24 hr. (Fig. 9). 
In addition, there was a significant increase in proliferation (> 20%) over 
the serum controls for concentrations > 40 ng/ml (Fig. 9).
The expression of SHP-1 after the addition of EOF differs from that 
of the serum controls. Unlike the cytoplasmic distribution of SHP-1 in 
serum cultures (Fig, lOB), the distribution of SHP-1 after the addition of
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Figure 9: The ratio o f the number o f BrdU+ cells after EGF treatment for 24 
hr. over control cultures. The Y-axis represents the ratio o f BrdU-labeled cells 
over controls in nine random fields within each culture. The significance was 
determined using a one-way ANO VA, p < 0.0001-0.05. EGF significantly 
increased proliferation at all concentrations (20-320 ng/ml) when compared to 
growth arrested cultures. In addition, there was a significant increase in 
proliferation ( > 20%) over the serum controls for concentrations_> 40 ng/ml.
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Fig. 10. SHP-1 immunoreactivity 24 hr. following the addition of growth 
factors. A) SHP-1 immunostaining in growth arrested cultures (Day-16). 
SHP-1 immunoreactivity is localized to the nucleus (arrows). B) SHP-1 
immunostaining in cultures after the réintroduction of serum (Day-16). 
Note the cytoplasmic distribution of SHP-1 staining (arrows). C and D- 
SHP-1 immunostaining after the addition of EGF (Day-16). C) Many cells 
display a dark area of staining located just below the nucleus (arrows). D) 
Other cells exhibit a nuclear distribution of immunoreactivity (arrows). E) 
SHP-1 immunostaining after the addition of GM-CSF (Day-16). Many 
large, vacuolated cells are darkly stained for SHP-1 (arrows). Some cells 
have both cytoplasmic and nuclear staining (arrow). F) SHP-1 
immunostaining after the addition of IL-3 (Day-16). Note the many large, 
vacuolated inununopositive cells (arrows) that resemble those seen 
following GM-CSF treatment. Bar=30 jim
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EGF appears to be largely nuclear (Fig. IOC, D). This is a similar staining 
pattern to that of the growth arrested cultures (Fig. 10A) with strong 
inununopositive staining in or around the nucleus. Small, dense areas of 
immunostaining located just below the nuclear membrane can also be seen 
in approximately 80% the EGF treated cultures (Fig. IOC).
GM-CSF addition
GM-CSF treatment has been shown to regulate mitogenic signaling 
in mouse macrophages as well as potentially dephosphorylating novel 
substrates critical for GM-CSF signaling (Yang et al. 1998), making it a 
potential candidate for influencing SHP-1 expression following injury. 
GM-CSF was therefore introduced to growth arrested cultures on day 15 
for 24 hours and the cultures were then pulsed with BrdU as described 
above. GM-CSF increased cellular proliferation by at least two-fold over 
serum depleted cultures at all concentrations (10-640 ng/ml; Fig. 11). GM- 
CSF also induced a 36% increase in proliferation over serum addition at 
concentrations > 40 ng/ml (Fig. 11).
Addition of GM-CSF results in a subset of cells that display dark 
cytoplasmic as well as nuclear staining (Fig. lOE). This contrasts with the 
expression pattern seen in growth arrested or serum treated cultures, which 
contain a nuclear or cytoplasmic distribution, respectively (Fig. 10A, B). In 
addition, many of the SHP-1+ cells appear to have vacuolated staining in 
the cytoplasm, which may reflect immunostaining around mitochondrial 
membranes (Fig. lOE).
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Figure 11: The ratio of the number of BrdU+ cells after GM-CSF 
treatment for 24 hr. over control cultures. The Y-axis represents the ratio 
of BrdU-labeled cells over controls in nine random fields within each 
culture. The significance was determined using a one-way ANOVA, p < 
0.0001-0.05. GM-CSF significantly increased proliferation at all 
concentrations (10-640 ng/ml) when compared to growth arrested 
cultures. In addition, there was a significant increase in proliferation ( > 
36%) over the serum controls for concentrations _> 40 ng/ml.
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IL-3 addition
SHP-1 has been found to bind to, and dephosphoryiate interleukin- 
3 (IL-3) in myeloid cells. However, its effects on avian neural and glial 
cells are not known. Therefore, IL-3 was the third type of growth factor 
introduced into growth arrested cultures. Addition of IL-3 resulted in a 
1.8-fold increase in proliferation at all concentrations (2-44 ng/ml) over 
growth arrested cultures. Interestingly, unlike EGF and GM-CSF, IL-3 did 
not cause a significant increase in proliferation over serum addition (Fig. 
12).
The pattern of SHP-1 immunoreactivity following the addition of IL- 
3 is similar to that induced by GM-CSF. Some cells contained very darkly 
labeled cytoplasm and nucleus and some areas of the cultures contained 
cells with nuclear staining only (Fig. lOF). In addition, the vacuolated 
pattern of immunostaining seen with GM-CSF as also seen with IL-3 (Fig. 
lOF).
Finally, no additional increase in cellular proliferation was observed 
when growth factors were added to cultures for 72 rather 24 hours (data 
not shown). In fact, BrdU incorporation decreased slightly at 72 hours, 
presumably because the cultures were confluent by this time. Likewise, 
cultures which had been treated for 24 and 72 hours did not differ in SHP- 
1 expression or distribution.
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Figure 12: The ratio of the number of BrdU+ cells after IL-3 treatment 
for 24 hr. over control cultures. The Y-axis represents the ratio of BrdU- 
labeled cells over controls in nine random fields within each culture. The 
significance was determined using a one-way ANOVA, p < 0.0001. IL-3 
significantly increased proliferation at all concentrations (2-44 ng/ml) 
when compared to growth arrested cultures.
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NMDA
Injury to the CNS in vivo often results in degeneration of neural 
cell bodies and their processes. It may be that neuronal debris plays a role 
in signaling the upregulation of SHP-1 expression in the brain following 
damage. In order to investigate this possibility, NMDA was added to 
confluent cultures presumably to excitotoxically kill neurons but leave 
glial cells intact. Both control cultures and NMDA-treated cultures were 
then examined for the distribution of SHP-1+ and GFAP+ glia within the 
entire culture as well as relative to intact and damaged neurons.
In control cultures, SHP-1+ and GFAP+ cells were found distributed 
throughout the culture as well as underneath or directly adjacent to the 
neurons (Figs. 13A, 14A). The addition of NMDA to cells at day 11 in 
culture resulted in neuronal degeneration at concentrations of 75-lOOpM 
after 48hrs. At these toxic concentrations, SHP-1+ cells were now found 
to be located some distance away from dying neurons and neuronal debris 
(Fig. 13B). While clusters of SHP-1+ cells could be observed in areas of 
the culture that did not contain neurons (data not shown), cells 
underneath and/or directly adjacent to dying neurons and neuronal 
fragments were SHP-1 negative (Fig. 13B). In contrast, GFAP 
immunoreactivity increased both beneath and surrounding dying neurons 
and neuronal debris (Fig. 14B). In addition, there appears to be an overall 
increase in GFAP+ astrocytes throughout the cultures 48hrs following the 
addition of toxic concentrations of NMDA.
It is important to note that this increase in GFAP immunoreactivity 
does not appear to be correlated with an increase in glial proliferation. The
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addition of NMD A (25-100 |xM) did not result in a significant increase in 
proliferation at either 24 (Fig. 15) or 48 hours (Fig. 16).
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Fig. 13 Mixed neural/glial culture immunostained for neurofilament and 
SHP-1. A) Control culture (Day-13). The SHP-1+ cells (arrows) surround 
the neuron and it’s processes (shown in green). B) Following 48 hr. of 
100 ixM NMDA, there is a decrease in SHP-1 + cells (arrows) around the 
dying neuron. Bar=80|im
46
/
47
Fig. 14. Mixed neural/glial culture immunostained for neurofilament and 
GFAP. A) Control culture (Day-13). The GFAP+ cells (arrows) surround 
the neuron and it’s processes (shown in green). B) Following 48 hr. of 
100 \\M  NMDA, there is a dramatic increase in GFAP+ cells (arrows) 
around and beneath the dying neuron. Bar=80|im
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Figure 15: The ratio of the number of BrdU+ cells after NMDA treatment for 24 
hr. over control cultures. The Y-axis represents the ratio of BrdU-labeled cells 
over controls in nine random fields within each culture. NMDA did not
significantly increase proliferation at any concentrations (25-100 pM).
48 hours after addition of NMDA
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Figure 16; The ratio of the number of BrdU+ cells after NMDA treatment for 48 hr. 
over control cultures. The Y-axis represents the ratio of BrdU-labeled cells over 
controls in nine random fields within each culture. NMDA did not significantly
increase proliferation at any concentrations (25-100 pM).
DISCUSSION
A subset of astrocytes, oligodendrocytes, and microglia within 
mixed neural/glial cultures of the chiçk auditory brainstem are 
immunopositive for SHP-1. Neurons do not appear to express SHP-1. This 
distribution differs from previous in vivo findings where deafferentation of 
the avian auditory brainstem results in an increase in SHP-1 
immunoreactivity within astrocytes only (Lurie et al. 1998). In this injury 
model, the onset of increased SHP-1 immunoreactivity is correlated 
temporally with an increase in astrocyte proliferation, and astrocytes are 
the only class of glia that proliferate following deafferentation in the 
chicken auditory brainstem. SHP-1 + astrocytes do not appear to be those 
which enter the cell cycle and it has been hypothesized that the 
expression of SHP-1 plays a role in negatively regulating the mitotic 
behavior of astrocytes following deafferentation or other injury (Lurie et 
al. 1998) perhaps in order to prevent a pathological formation of large glial 
masses at the lesion site. The hypothesis that SHP-1 expression may 
negatively regulate astrocyte proliferation is in agreement with 
observations in other systems where SHP-1 activity has been found to be 
inversely related to growth and proliferation of cells (Lopez et al. 1996; 
1997; Cambillau et al. 1995;Uchida et al. 1993; Zhao et al. 1994; Yi et al. 
1993).
Our present finding that SHP-1 is present in microglia and 
oligodendrocytes as well as astrocytes in vitro, may reflect the fact that aU 
three glial subtypes would be expected to proliferate in culture. If SHP-1 is 
expressed in those populations of cells that are dividing in order to 
regulate the extent of cell division, then it is not unexpected that a subset
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of all glial cells are immunopositive for SHP-1 while neurons do not label 
for the enzyme. However, we have not yet been able to directly show that 
SHP-1 + cells are not BrdU positive. Studies are currently underway using 
other cell cycle markers such as cyclin antibodies to confirm that SHP-1+ 
glial cells do not proliferate. Interestingly, to date, astrocytes have been 
the only glial cell type that have been described to contain SHP-1. The 
present study is the first report of SHP-1 expression in microglia and 
oligodendrocytes (Lurie et al. 1998; Massa and Wu. 1996).
Manipulation of the cell cycle
Manipulating the cell cycle of the mixed neural/glial cultures alters 
both the number of immunoreactive cells and the distribution of SHP-1 
staining. Specifically, growth arrest of the cultures results in large areas 
that contain no SHP-1 immunoreactivity. However, there are clusters of 
SHP-l-k cells that are widely scattered throughout the culture. These 
immunopositive cells show a nuclear rather than a cytoplasmic distribution 
of SHP-1 staining, indicating that the enzyme has translocated to the 
nucleus following growth arrest. This observation is in agreement with 
published reports in other systems, where the redistribution of SHP-1 in 
response to signaling has been noted. For example, the phorbol ester, 
phorbol 12-myristate 13-acetate (PMA) has been shown to induce SHP-1 
expression as well as produce a translocation of SHP-1 from the cytoplasm 
to a plasma membrane (Zhao et al. 1994). In addition, growth hormone has 
been shown to both increase SHP-1 activity and induce a translocation of 
most of the enzyme from the cytoplasm to the nucleus in rat liver cells
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(Ram and Waxman 1997). Finally, localization of SHP-1 may reflect its 
activity. When the enzyme is localized to the cytosol of HL-60 cells, its 
activity is at a minimum, but when a lipoprotein such as PMA is added, the 
enzyme translocates to a lipid membrane and its activity is increased 10̂  to 
10"̂  fold (Zhao et al. 1994). It may be that the translocation we observe 
during growth arrest reflects the activity of SHP-1. Our laboratory is in the 
process of developing a SHP-1-specific activity assay that should yield 
insight into the enzymatic activity of SHP-1 during localization to the 
cytoplasm vs. the nucleus.
One factor that should be considered in these studies is the fact that 
we were unable to completely growth arrest the cultures. Serum 
deprivation for 6 days was found to significantly growth arrest the 
cultures, but not completely eliminate all cell division. We attempted to 
extend the time in the serum free-medium (B-27) but were never able to 
completely stop all cell division. In addition, when the time in serum-free 
medium was extended, the cultures became slightly more confluent, thus 
decreasing the amount of inducible proliferation after serum was re­
introduced. We also found that the amount of proliferation after re- 
introduction of serum was slightly less than the proliferation observed 
during the initial growth stage. This was presumably due to the fact that 
the cultures were slightly more confluent following the 6 days of semm 
deprivation and contact inhibition may a played a role in reducing the 
amount of glial proliferation. Ara-C was also used in our initial 
experiments in an attempt to completely stop all cell division. However, 
concentrations of Ara-C that were not toxic to the cells did not
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successfully stop all proliferation, while higher concentrations resulted in 
cellular degeneration.
It is clear, though, that the expression of SHP-1 immunoreactivity 
changes during the three different growth conditions: serum (initial 
growth), serum-deprivation (growth arrested), and réintroduction of serum 
(growing). The observation that the immunoreactivity of SHP-1 changes 
when the cultures are actively dividing versus growth arrested, supports 
the hypothesis that SHP-1 may be involved in those cellular cascades that 
regulate the cell cycle. Its role is likely to be very complex in light of the 
fact that SHP-1 immunostaining is not eliminated during growth arrest and 
areas of the culture contain groups of cells that are SHP-1+. These clusters 
of SHP-I+ cells do not appear to be correlated with areas of dividing cells, 
those few remaining BrdU+ cells are widely scattered throughout the 
growth arrested cultures and are not localized to any particular region. 
The finding that the SHP-1 enzyme appears to be located in different 
cellular compartments (i.e. cytoplasmic vs. nuclear) when cells are 
proliferating versus when they are quiescent is intriguing, and may reflect 
functional properties of this enzyme.
Sodium orthovanadate
The hypothesis that SHP-1 plays a role in negatively regulating the 
glial cell cycle was tested by the addition of sodium orthovanadate. 
Vanadate is a general FTP inhibitor (Swamp et al. 1982) whose 
mechanisms of actions have not been investigated in detail, but have been 
shown to inhibit SH2 domain containing tyrosine phosphatases
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(Pugazhenthi et al. 1996; Huyer et al. 1996). Vanadate is a phosphate 
analog and is generally thought to bind as a transition state analog to the 
phosphoryl transfer enzymes that it inhibits, since it can easily adopt a 
trigonal-bipyramidal structure (Goldfine et al. 1995). Vanadate has a wide 
array of effects on biological systems (Shechter 1990). It is an insulin- 
mimetic and has been shown in human clinical trials to be potentially 
useful in treating both insulin- and non-insulin-dependent diabetes and it 
has been suggested that part of vanadate’s insuhn-mimetic effect may be 
due to its inhibition of FTPs (Shechter 1990). However, vanadate is a non­
specific tyrosine phosphatase inhibitor and will thus inhibit the activity of 
SHP-1 as well as other tyrosine phosphatases.
The addition of vanadate into growing cultures resulted in an 
increase in cellular proliferation over serum control. Thus, inhibition of 
phosphatase activity did increase the number of BrdU labeled cells, 
indicating a strong correlation between tyrosine phosphatase activity and 
inhibition of cellular proliferation. Vanadate has also been shown to alter 
the regulation of IFN-gamma-signaling in mouse astrocytes in similar ways 
to astrocytes that do not contain SHP-1 (Massa and Wu 1996), implicating 
a role for SHP-1 in this signaling cascade. However, it is clear that a 
specific inhibitor for SHP-1 will have to be developed in order to 
definitively show that SHP-1 is a key player in these systems and is the 
phosphatase that negatively regulates glial proliferation in the avian 
brainstem.
The addition of vanadate did not appear to significantly alter SHP-1 
expression and/or distribution within the cultures. Quantification of the
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amount of immunostaining throughout the entire culture did not reveal 
any significant differences at any of the concentrations of vanadate. 
Specifically, vanadate neither increased nor decreased the total amount of 
SHP-1 expressed within the culture. Visual inspection revealed that 
perhaps a slight increase in the density of SHP-1 staining within some 
individual glial cells occurred with the addition of vanadate, but this did 
not seem to be the case for every SHP-1 + cell. Finally, SHP-1 
immunoreactivity remained localized to the cytoplasm following vanadate 
treatment and did not appear to translocate to the nucleus. Thus, 
inhibition of tyrosine phosphatase activity does not seem to alter either the 
amount, or localization, of SHP-1 immunoreactivity within our culture 
system.
Growth factors
Both the signals that activate SHP-1 in vivo, as well as its substrates, 
are as yet unknown and the signal transduction pathway of SHP-1 has not 
been fully elucidated. However, SHP-1 is involved in growth factor 
mediated signal transduction in a variety of different cells. For example, 
SHP-1 binds to the interleukin 3 (IL-3) receptor following ligand binding 
(Yi and Ihle 1993) and also associates with, and can dephosphorylate, 
activated EOF receptors (You and Zhao 1997; Tenev et al. 1997; Tomic et 
al. 1995). In addition, SHP-1 has been shown to play an important role in 
downregulating GM-CSF mitogenic signaling in motheaten macrophages 
(Yang et al. 1997). Our finding that the addition of these three growth 
factors (EOF, IL-3, and GM-CSF) to our serum depleted cultures resulted in
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increased cellular proliferation confirms that these growth factors are 
mitogenic for avian CNS cells. All three of these factors have been shown 
to be mitogenic for astrocytes in vitro in other systems (Langan et al. 
1994; Huff and Scheier 1990; Malhotra et al. 1990) and have also been 
demonstrated to interact with SHP-1.
Growth factors and their receptors are excellent candidate signaling 
molecules for SHP-1 and other tyrosine phosphatases due to the fact that 
growth factor receptors of the tyrosine kinase-type undergo rapid 
autophosphorylation upon ligand stimulation (Schlessinger and Ullrich 
1992; Fantl et al. 1993). This autophosphorylation generates binding sites 
for SH2 domain containing intracellular proteins. Membrane recruitment 
of these molecules by binding to the autophosphorylated growth factor 
receptors is considered an important step in the activation of several 
intracellular signaling cascades which ultimately lead to cellular responses 
such as cellular division, differentiation, or locomotion (Schlessinger and 
Ullrich 1992). Dephosphorylation of the autophosphorylated growth 
factor receptors by PTPases presents a major mechanism of negative 
regulation of tyrosine kinase receptor signaling. SHP-1 has been shown to 
interact with multiple growth factors and their receptors and to modulate 
their activity (Schlessinger and Ullrich 1992; Feng and Pawson 1994), 
which could presumably lead to alterations in cell division and 
differentiation.
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EGF
SHP-1 has been shown to associate with and dephosphorylate 
epidermal growth factor receptors (Tomic et al. 1995; Tenev et al. 1997; 
You and Zhao. 1997). Inactivation of SHP-1 by a point mutation of the C- 
terminus SH2-domain slightly reduces its association with the EGF 
receptor, but a point mutation at the N-terminus SH2-domain leads to a 
large reduction in association, indicating that the SH2-domain responsible 
for binding of SHP-1 to the EGF receptor is the N-terminus SH2 domain 
(Tenev et al. 1997). Thus, the catalytic domains of SHP-1 are thought to 
provide specificity for the interaction with the EGF receptor although 
functional interactions of SHP-1 with the EGF receptor requires 
association that is mediated by both SH2 domains (Tenev et al. 1997).
The addition of EGF for 24 hours to our serum deprived cultures led 
to at least a two-fold increase in BrdU-incorporation at all concentrations 
examined. EGF also induced significantly more proliferation than serum at 
concentrations of 40 ng/ml and higher. This result was not unexpected 
given that EGF has been shown to be mitogenic for astrocytes in other in 
vitro systems (Langan et al. 1994; Huff and Scheier 1990; Malhotra et al. 
1990). In addition to increased proliferation, EGF resulted in a nuclear 
distribution of SHP-1 in those cells that were immunoreactive. This dark 
nuclear immunostaining of SHP-1 resembled the nuclear staining of SHP-1 
when the cultures were growth arrested. Dark areas of perinuclear 
immunoreactivity could also be seen following EGF treatment. The 
relationship between this pattern of SHP-1 immunoreactivity and its
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activity following EGF stimulation remains to be elucidated. Intriguingly, 
SHP-1 is thought to play a positive role in EGF-activated mitogenesis in 
human embryonic kidney cells (Su et al, 1996). Whether SHP-1 plays a 
positive or negative role in EGF-activated mitogenesis in avian CNS 
cultures will require further studies.
GM-CSF
SHP-1 has been shown to be involved in downregulating GM-CSF 
mitogenic signaling in motheaten macrophages and may also 
dephosphorylate novel substrates critical for GM-CSF signaling in these 
macrophages (Yang et al. 1997). GM-CSF has also been shown to be 
secreted by astrocytes and can stimulate the in vitro proliferation of simian 
astrocytes (Guillemin et al. 1996), as well as induce IL-6 production by 
mouse microglia (Suzumura et al. 1996). Finally, GM-CSF has also been 
demonstrated to result in microglial proliferation and can also facilitate the 
ramification of rat microglia in vitro (Fujita et al. 1996; Lee et al. 1994).
The addition of GM-CSF to our cultures caused an increase in 
proliferation similar to that seen with the addition of EGF, indicating that 
GM-CSF is mitogenic for avian CNS cells. GM-CSF also induced a 36% 
increase in proliferation over serum addition at concentrations > 40 ng/ml. 
However, the immunostaining for SHP-1 differed from that seen with EGF 
in that GM-CSF induced a cytoplasmic as well as a nuclear distribution. 
The cytoplasmic staining often appeared vacuolated, which may reflect 
immunoreactivity around mitochondrial membranes. It is interesting that 
both EGF and GM-CSF result in a similar increase in proliferation but have
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very different patterns of SHP-1 immunoreactivity. It may be that GM-CSF 
and EGF act on different types of cells within our mixed neural/glial 
cultures or that the differential staining pattern reflects different functional 
states of SHP-1.
IL-3
IL-3 has been detected in hippocampal and septal murine neurons 
(Konishi et al, 1994) as well as rat microglial cells (Gebicke-Haerter et al. 
1994; Ganter et al. 1992). Microglia have also been found to express 
mRNA for IL-3 receptors (Sawada et al. 1993). SHP-1 has been shown to 
associate with the IL-3 receptor and may also regulate mitogenic signaling 
by IL-3 (Yang et al. 1998; Yi et al. 1993; Bone et al. 1997). IL-3 is a potent 
mitogen for microglia both in vivo and in culture (Gebicke-Haerter et al. 
1994; Ganter et al. 1992) and SHP-1 may play a role in this signaling 
cascade. SHP-1 has been shown to bind to IL-3 in the cytosol of the cells 
after it has been internalized and may regulate IL-3 mediated signal 
transduction pathways (Bone et al. 1997).
The addition of IL-3 to our growth arrested cultures resulted in an 
increase in proliferation similar to that seen with EGF and GM-CSF. 
However, no concentration of IL-3 tested produced a significant increase 
in proliferation over the addition of serum. The pattern of SHP-1 
immunoreactivity following the addition of IL-3 was similar to that 
induced by GM-CSF rather than serum or EGF.
This similarity in SHP-1 immunoreactivity between GM-CSF and IL- 
3 may reflect similarities in 1) the structure of GM-CSF and IL-3 receptors
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and 2) the mediation of mitogenic signal transduction. The receptors for 
GM-CSF and IL-3 share a common beta chain and both growth factors, as 
well as EGF use tyrosine phosphorylation to control proliferation (Mire- 
Sluis et al. 1995). Of particular interest is the finding that GM-CSF and IL- 
3-induced proliferation is stimulated by a tyrosine phosphatase inhibitor in 
a human erythroleukemia cell line while IL-5 induced proliferation is 
inhibited (Mire-Sluis et al. 1995). Both growth factors also induce 
microglial proliferation. The large, darkly stained and vacuolated SHP-1+ 
cells that are present in our cultures following GM-CSF and IL-3 treatment 
resemble the OX42-labeled microglia. In contrast, the SHP-1+ cells that are 
present following EGF treatment appear to be much smaller cells and more 
closely resemble astrocytes. It may be that EGF induces SHP-1 expression 
primarily in astrocytes while GM-CSF and IL-3 induce SHP-1 expression in 
microglia. Further studies are needed to confirm this hypothesis. It would 
also be of interest to determine whether EGF results in astrocyte 
proliferation while GM-CSF and IL-3 results in microglial proliferation.
NMDA
Following deafferentation of the chick auditory brainstem, SHP-1 
immunoreactivity increases to a peak three days following cochlea removal 
(Lurie et al. 1998). At this time, there is a 30% neuronal loss with 
accompanying axonal degeneration in the primary auditory nucleus. It 
may be that this neuronal cell death plays a role in the upregulation of 
SHP-1 immunoreactivity in vivo.
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Therefore, NMDA was added to the avian brainstem cultures in 
order to kill neurons and leave the glial cells intact. NMDA is a known 
selective glutamate receptor agonist and is found on neuronal post 
synaptic terminals. Application of NMDA results in excitotoxic neuronal 
death due to excessive activation of NMDA receptors. To date no known 
NMDA receptors have been found on glial cells and therefore NMDA is 
thought to induce excitotoxicity in neurons only. Over-activation of 
NMDA receptors leads to an increase of Ca^  ̂ into the cell (Ferreira et al. 
1996), which in turn activates several cascades ultimately leading to 
neuronal death. These cascades include activation of phospholipases and 
proteases, cellular breakdown, and DNA fragmentation (Lynch and 
Dawson 1994).
Application of NMDA to our cultures resulted in neuronal 
degeneration but did not appear to induce any increases in cellular 
proliferation. However, due to technical considerations, we have not yet 
been able to double-label cultures for both BrdU and neurofilament in 
order to determine whether glial proliferation increased around 
degenerating neurons. Careful examination of BrdU-labeled cultures that 
have been treated with neurotoxic concentrations of NMDA reveals a 
fairly uniform distribution of proliferative cells rather than clusters of 
BrdU+ cells.
In contrast to undamaged neurons, most degenerating neurons are 
located in areas that are devoid of SHP-1 immunostaining. In untreated 
cultures, SHP-1+ cells are found throughout the culture, and many neurons 
are surrounded by SHP-1 immunoreactivity. Following NMDA treatment,
62
clusters of SHP-1+ cells are located at a distance from the dead or dying 
neurons, but few SHP-1 + cells remain directly adjacent to the neuronal 
fragments. This differs from the pattern of GFAP immunoreactivity, where 
many GFAP+ astrocytes are located around and beneath the dying 
neurons. These results are particularly intriguing given the fact that our in 
vivo findings indicate that at least initially following deafferentation, SHP- 
1+ astrocytes represent a different population of cells than the GFAP+ 
astrocytes (Lurie et al. 1998). It may be that neuronal degeneration 
induces the activation of GFAP+ astrocytes while other factors are 
involved in signaling an increase in SHP-1 + glia.
Conclusions
Based upon the information presented for this thesis, several 
conclusions can be drawn:
1. Manipulation of the cell cycle in chick brainstem cultures was 
successfully accomplished and this manipulation changed the distribution 
of SHP-1 immunoreactivity..
2. The cell types that contain SHP-1 are of glial origin demonstrating 
that SHP-1 is expressed in those cells which are able to proliferate after 
injury in vitro.
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3. Introduction of the protein tyrosine phosphatase inhibitor, sodium 
orthovanadate, increased the proliferation of the cultures indicating a 
relationship between phosphatase activity and the regulation of 
proliferation.
4. Addition of specific growth factors (IL-3, EGF and GM-CSF) 
resulted in different expression patterns of SHP-1. It may be that SHP-1 is 
involved in more than one signal transduction cascade regulating cellular 
division.
5. Neuronal degeneration results in little SHP-1 immunoreactivity in 
the immediate vicinity of dead and dying neurons. This contrasts with 
GFAP+ astrocytes, which are located around and beneath areas of neural 
degeneration.
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